Inference of Tumor Phylogenies from Genomic Assays on Heterogeneous Samples.

Tumorigenesis can in principle result from many combinations of mutations, but only a few roughly equivalent sequences of mutations, or 'progression pathways,' seem to account for most human tumors. Phylogenetics provides a promising way to identify common progression pathways and markers of those p...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Biomedicine & Biotechnology Vol. 2012; pp. 1 - 17
Autores principales: Subramanian, Ayshwarya, Shackney, Stanley, Schwartz, Russell
Formato: equations & formulas pictorial research tables/charts Journal Article
Publicado: Wiley-Blackwell 2012
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Tumorigenesis can in principle result from many combinations of mutations, but only a few roughly equivalent sequences of mutations, or 'progression pathways,' seem to account for most human tumors. Phylogenetics provides a promising way to identify common progression pathways and markers of those pathways. This approach, however, can be confounded by the high heterogeneity within and between tumors, which makes it difficult to identify conserved progression stages or organize them into robust progression pathways. To tackle this problem, we previously developed methods for inferring progression stages from heterogeneous tumor profiles through computational unmixing. In this paper, we develop a novel pipeline for building trees of tumor evolution from the unmixed tumor data. The pipeline implements a statistical approach for identifying robust progression markers from unmixed tumor data and calling thosemarkers in inferred cell states. The result is a set of phylogenetic characters and their assignments in progression states to which we apply maximum parsimony phylogenetic inference to infer tumor progression pathways. We demonstrate the full pipeline on simulated and real comparative genomic hybridization (CGH) data, validating its effectiveness and making novel predictions of major progression pathways and ancestral cell states in breast cancers.